This company has been marked as potentially delisted and may not be actively trading. resTORbio (TORC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TORC vs. VIRI, ATOS, CRVO, VTYX, AVTE, EPIX, VERU, CRBP, IFRX, and IGMSShould you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Virios Therapeutics (VIRI), Atossa Therapeutics (ATOS), CervoMed (CRVO), Ventyx Biosciences (VTYX), Aerovate Therapeutics (AVTE), ESSA Pharma (EPIX), Veru (VERU), Corbus Pharmaceuticals (CRBP), InflaRx (IFRX), and IGM Biosciences (IGMS). These companies are all part of the "medical" sector. resTORbio vs. Virios Therapeutics Atossa Therapeutics CervoMed Ventyx Biosciences Aerovate Therapeutics ESSA Pharma Veru Corbus Pharmaceuticals InflaRx IGM Biosciences Virios Therapeutics (NASDAQ:VIRI) and resTORbio (NASDAQ:TORC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends. Which has more volatility and risk, VIRI or TORC? Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, resTORbio has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Do analysts prefer VIRI or TORC? Virios Therapeutics currently has a consensus price target of $3.00, indicating a potential downside of 45.26%. Given Virios Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Virios Therapeutics is more favorable than resTORbio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50resTORbio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is VIRI or TORC more profitable? resTORbio's return on equity of -78.12% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% resTORbio N/A -78.12%-71.63% Does the MarketBeat Community prefer VIRI or TORC? resTORbio received 138 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 67.14% of users gave resTORbio an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote. CompanyUnderperformOutperformVirios TherapeuticsOutperform Votes350.00% Underperform Votes350.00% resTORbioOutperform Votes14167.14% Underperform Votes6932.86% Which has higher valuation and earnings, VIRI or TORC? Virios Therapeutics is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-20.30resTORbioN/AN/A-$82.74M-$2.41-0.27 Do institutionals & insiders have more ownership in VIRI or TORC? 9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 46.2% of resTORbio shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by company insiders. Comparatively, 11.8% of resTORbio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to VIRI or TORC? In the previous week, Virios Therapeutics' average media sentiment score of 0.00 equaled resTORbio'saverage media sentiment score. Company Overall Sentiment Virios Therapeutics Neutral resTORbio Neutral SummaryresTORbio beats Virios Therapeutics on 7 of the 13 factors compared between the two stocks. Get resTORbio News Delivered to You Automatically Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TORC vs. The Competition Export to ExcelMetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.14M$6.74B$5.50B$7.96BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-0.377.3822.6318.55Price / SalesN/A241.88397.30103.38Price / CashN/A65.8538.1834.62Price / Book0.306.476.704.25Net Income-$82.74M$143.68M$3.23B$248.27M resTORbio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TORCresTORbioN/A$0.66+6.4%N/A-58.2%$24.14MN/A-0.37N/AGap UpVIRIVirios TherapeuticsN/A$4.27+14.5%$3.00-29.7%+1,094.5%$82.23MN/A-15.815Upcoming EarningsATOSAtossa Therapeutics1.9487 of 5 stars$0.64+2.2%$7.13+1,019.2%-40.5%$82.23MN/A-2.898Gap UpCRVOCervoMed3.6008 of 5 stars$9.30-5.1%$27.50+195.7%-62.7%$80.94M$7.14M-4.584VTYXVentyx Biosciences2.5071 of 5 stars$1.13+5.6%$10.00+785.0%-64.4%$80.38MN/A-0.4830Upcoming EarningsNews CoveragePositive NewsAVTEAerovate Therapeutics0.4014 of 5 stars$2.77+0.7%$2.25-18.8%-49.3%$80.29MN/A-0.9320Earnings ReportOptions VolumeNews CoverageEPIXESSA Pharma3.1665 of 5 stars$1.77-1.1%$9.50+436.7%-71.7%$78.57MN/A-2.5750VERUVeru2.1545 of 5 stars$0.52-2.1%$4.33+728.7%-59.9%$78.20M$16.89M-2.01230Upcoming EarningsNews CoveragePositive NewsCRBPCorbus Pharmaceuticals4.0346 of 5 stars$6.30+4.5%$59.13+838.5%-79.8%$77.06MN/A-1.3440Upcoming EarningsIFRXInflaRx2.5638 of 5 stars$1.14+7.5%$9.00+689.5%+24.1%$76.53M$165,789.00-1.0660Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageIGMSIGM Biosciences4.3409 of 5 stars$1.28+4.9%$5.50+329.7%-85.6%$76.51M$2.68M-0.35190Upcoming EarningsNews Coverage Related Companies and Tools Related Companies Virios Therapeutics Alternatives Atossa Therapeutics Alternatives CervoMed Alternatives Ventyx Biosciences Alternatives Aerovate Therapeutics Alternatives ESSA Pharma Alternatives Veru Alternatives Corbus Pharmaceuticals Alternatives InflaRx Alternatives IGM Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TORC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share resTORbio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TORC Stock Free TORC Stock Alerts